Fierce Biotech1 min read
saveKyverna reports year-long efficacy and clean safety for miv-cel CAR-T in autoimmune trials
read at Fierce Biotech ↗Positive readoutPositive
Kyverna Therapeutics released one-year data for its CAR-T candidate miv-cel in stiff person syndrome and 18-month data in generalized myasthenia gravis.
The single dose showed durable clinical benefit, with remission lasting up to 12 months in SPS and up to 18 months in gMG.
No high-grade cytokine release syndrome, ICANS, or IEC-HS events were observed, indicating a clean safety profile.
The company will add the one-year data to its FDA rolling submission for SPS, keeping the filing on track for completion in the fourth quarter.
source
This writeup was produced by pharmadog from original reporting by Fierce Biotech.
Original headline: “Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags”
read at Fierce Biotech ↗1,123 words · retrieved Sep 24
comments(0)
5-min edit window · permanent after that